<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01367145</url>
  </required_header>
  <id_info>
    <org_study_id>OMACOR II - 2011</org_study_id>
    <nct_id>NCT01367145</nct_id>
  </id_info>
  <brief_title>OMEGA-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Peripheral Arterial Disease</brief_title>
  <official_title>OMEGA-3-POLYUNSATURATED FATTY-ACIDS (n3-PUFA) IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE: EFFECTS ON ENDOTHELIAL FUNCTION - A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal aim of the study is to determine the effects n3-PUFA on top of standard therapy
      on surrogate markers of disease severity and/or prognosis in patients with PAD.

      Treatment duration will be 3 months, final follow-up is planned at 6 months after inclusion.

      Primary outcome parameter is endothelial function assessed by flow-mediated vasodilation
      using brachial artery ultrasound.

      Secondary outcome measures comprise maximum and pain-free treadmill walking distance, pulse
      wave velocity, whole blood viscosity, platelet activation and plasma markers of inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline endothelial function to 3 months</measure>
    <time_frame>baseline, 3 months</time_frame>
    <description>measured by flow mediated vasodilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline endothelial function to six months</measure>
    <time_frame>baseline, 6 months (3 months after treatment cessation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of walking distance (maximum/pain-free)from baseline to three months and six months</measure>
    <time_frame>baseline, 3, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of inflammatory markers from baseline to one, three and six months</measure>
    <time_frame>baseline, 1, 3, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of pulse wave velocity from baseline to one, three and six months</measure>
    <time_frame>baseline, 1, 3, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding events</measure>
    <time_frame>1, 3, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver enzymes changes</measure>
    <time_frame>baseline, 1,3,6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of platelet activation from baseline to one, three and six months</measure>
    <time_frame>baseline, 1, 3, 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Omacor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMACOR</intervention_name>
    <description>4 capsules OMACOR 1g per day</description>
    <arm_group_label>Omacor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 capsules placebo per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severity of disease: Rutherford category II or III - moderate to severe Stable
             intermittent claudication

          -  Ankle Brachial Index&lt;0.9

          -  Age â‰¥18 years

          -  Adequate PAD therapy according to current AHA guidelines

        Exclusion Criteria:

          -  Current treatment with Omacor or other fish oil products

          -  Planned vascular intervention

          -  Known hypersensitivity to the study drug

          -  Rest pain or ischemic ulcer

          -  Exercise tolerance limited by factors other than PAD

          -  Inability to perform treadmill test

          -  Dual antiplatelet therapy (aspirin and clopidogrel)

          -  Previous myocardial infarction

          -  Known liver diseases, except fatty liver

          -  Known bleeding diathesis

          -  Women of childbearing potential who do not practice a safe contraception method

          -  Current participation in another intervention study.

          -  Previous participation in another study with an intervention within the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Steiner, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Internal Medicine II, Division of Angiology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2011</study_first_posted>
  <last_update_submitted>August 24, 2014</last_update_submitted>
  <last_update_submitted_qc>August 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Sabine Steiner</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>OMEGA-3 polyunsaturated fatty-acids</keyword>
  <keyword>Peripheral Arterial Disease</keyword>
  <keyword>Endothelial Function</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Platelet Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

